Asymmetric anti-CLL-1×CD3 bispecific antibody, ABL602 2+1, with attenuated CD3 affinity endows potent antitumor activity but limited cytokine release

por Lee, Eunhee, Lee, Shinai, Park, Sumyeong, Son, Yong-Gyu, Yoo, Jiseon, Koh, Youngil, Shin, Dong-Yeop, Lim, Yangmi, Won, Jonghwa
Publicado 2023